Progress in the Development of Preventative Drugs for Cisplatin-Induced Hearing Loss.

about

CDK2 inhibitors as candidate therapeutics for cisplatin- and noise-induced hearing loss.

P2860

Q50420474-8481AC5B-0B26-4473-A354-FE48C85DEF49

P2860

Progress in the Development of Preventative Drugs for Cisplatin-Induced Hearing Loss.

Item

http://www.wikidata.org/entity/Q47716828

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Progress in the Development of Preventative Drugs for Cisplatin-Induced Hearing Loss.

@en

Progress in the Development of Preventative Drugs for Cisplatin-Induced Hearing Loss.

@nl

type

Item

label

Progress in the Development of Preventative Drugs for Cisplatin-Induced Hearing Loss.

@en

Progress in the Development of Preventative Drugs for Cisplatin-Induced Hearing Loss.

@nl

prefLabel

Progress in the Development of Preventative Drugs for Cisplatin-Induced Hearing Loss.

@en

Progress in the Development of Preventative Drugs for Cisplatin-Induced Hearing Loss.

@nl

P1476

Progress in the Development of Preventative Drugs for Cisplatin-Induced Hearing Loss

@en

P2093

Jaeki Min

http://www.w3.org/2001/XMLSchema#string

Robert A Hazlitt

http://www.w3.org/2001/XMLSchema#string

P2860

Sodium thiosulfate ameliorates oxidative stress and preserves renal function in hyperoxaluric rats

The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs

NOX3, a superoxide-generating NADPH oxidase of the inner ear

Reversible p53 inhibition prevents cisplatin ototoxicity without blocking chemotherapeutic efficacy

Dose-dependent protection on cisplatin-induced ototoxicity - an electrophysiological study on the effect of three antioxidants in the Sprague-Dawley rat animal model.

Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions.

Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma.

Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. EORTC Head and Neck Cooperative Group.

Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group study.

Application of antioxidants and other agents to prevent cisplatin ototoxicity.

P304

5512-5524

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/ACS.JMEDCHEM.7B01653

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jian Zuo

P577

2018-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29361217

http://www.w3.org/2001/XMLSchema#string

P921

inorganic compound

biomedical investigative technique

P932

6043375

http://www.w3.org/2001/XMLSchema#string

Progress in the Development of Preventative Drugs for Cisplatin-Induced Hearing Loss.

about

P2860

P2860

Progress in the Development of Preventative Drugs for Cisplatin-Induced Hearing Loss.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932